ArticleScientific reports2025
Evaluating triple inactivated vaccine-induced immunity from a large-scale study in feline population.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in Feline Panleukopenia Virus Vaccines: Immunological Mechanisms, Current Challenges, and Future Perspectives.Viruses · 2026Review
- Review
- Association Study on Risk Factors for Major Infectious Diseases in Dogs and Cats in Shenzhen, China.Animals : an open access journal from MDPI · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Feline panleukopenia virus (FPV), feline calicivirus (FCV), and feline herpesvirus-1 (FHV-1) substantially impact feline health. Field evidence on vaccine-induced population immunity remains limited. We evaluated humoral responses in 4,736 vaccinated domestic cats across 24 provinces in China (July 2024-June 2025), quantifying neutralizing antibody titers to FPV, FCV, and FHV-1 after a trivalent inactivated vaccine (Meowonder™). For cats aged 3 months or older, two primary doses achieved high antibody positivity rates across pathogens; a third dose yielded marginal additional benefit, while boosters-maintained titers. Antibody peaks occurred in late summer and early winter, with a decline beginning in February and a rebound in spring. Maternal-derived antibodies (MDAs) interfered most in kittens < 4 months. A subset with very high FPV titers but sub-threshold FCV/FHV-1 titers had recent environmental FPV based on pet owners' feedback. The variability of individual immune responsiveness, potentially influenced by feline leukocyte antigen (FLA) polymorphisms, likely contributed to heterogeneous responses. These results support a two-dose primary series for cats aged ≥ 3 months, followed by periodic boosters, emphasizing the importance of vaccine schedules and consideration of genetic and environmental factors for effective disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.